The Patients Over Profit (POP) Act makes it illegal for a single “person” to own, operate, or control both a health insurance issuer and an “applicable provider” (or a management services organization contracting with such a provider) that bills Medicare Part B or participates in Medicare Advantage. Entities that fall afoul of the prohibition must divest within statutory windows and are subject to civil enforcement by the HHS Inspector General, DOJ Antitrust Division, the FTC, or state attorneys general.
Beyond the ownership ban, the bill amends the Social Security Act to block Medicare Advantage contracting with organizations that violate the rule, requires MA organizations to certify compliance, treats claims submitted by violators as false claims, and directs disgorged revenues into an FTC-administered fund for affected communities. The measure reshapes how vertical integration between payers and providers is regulated in Medicare and adds new procedural hooks — Clayton Act reporting without usual thresholds, FTC rulemaking, and coordinated agency review — that will alter M&A, due diligence, and compliance practice for insurers, MA plans, and health systems.
At a Glance
What It Does
The bill forbids any person from simultaneously owning or controlling a health insurance issuer and an applicable Medicare provider (or an MSO contracted to such a provider). Violations trigger mandatory divestiture deadlines, agency civil actions, disgorgement of revenues, and FTC/DOJ review of divestitures.
Who It Affects
Medicare Advantage organizations, commercial insurers, management services organizations (MSOs) that contract with Medicare-billing clinicians, private equity and other investors holding mixed portfolios, and Medicare beneficiaries served by those entities.
Why It Matters
It sets a statutory limit on payer-provider vertical integration within the Medicare context, creates new avenues for antitrust-style enforcement, and may force restructuring of existing contracts and ownership arrangements—affecting M&A valuations, contracting practices, and network stability for MA plans.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill defines the core prohibition broadly: a ‘‘person’’ cannot directly or indirectly own, operate, or control any part of both (1) an ‘‘applicable provider’’—an entity that receives Medicare Part B or Medicare Advantage Part C payments for professional services, with narrow exclusions—and (2) a health insurance issuer. The text treats management services organizations separately by including MSOs that have management services agreements with applicable providers; ownership of an MSO tied to a provider counts as ownership of the provider for purposes of the ban.
When an ownership tie exists, the statute requires divestiture within set timelines: two years for combinations that existed before enactment and one year for acquisitions after enactment. Those deadlines pause if a waiting period under the Clayton Act Section 7A review is in progress.
The bill compels reporting of such divestitures to the FTC and DOJ regardless of the size thresholds that would normally trigger that reporting and tasks the FTC and DOJ with reviewing both the divestiture and any subsequent buyer’s impact on competition and financial viability.Enforcement is civil and multi‑agency. HHS’s Inspector General, the DOJ Antitrust Division, the FTC, or a state attorney general may sue to obtain injunctive relief, compel divestiture, and require disgorgement of revenues earned during the violation.
The bill specifies that disgorged amounts go into a fund established by the FTC to support health needs of harmed communities, while preserving individuals’ rights to bring separate claims. The FTC must also promulgate rules to implement the statute.The bill amends Medicare law to backstop the prohibition: the Secretary may not contract with or pay a Medicare Advantage organization that has the disallowed ownership relationship, starting with plan years on or after January 1, 2026.
It requires MA organizations to certify compliance and establishes that claims submitted by entities in violation constitute false or fraudulent claims under federal law. Part D is tied in by cross-reference.
The statute excludes hospitals, critical access hospitals, rural emergency hospitals, pharmacies, and DME suppliers from the ‘‘applicable provider’’ definition, narrowing the scope to physician-level and similar outpatient providers and their MSOs.
The Five Things You Need to Know
The ban covers ownership or control of both a health insurance issuer and either an ‘‘applicable provider’’ that bills Medicare Part B/MA or an MSO that has a management services agreement with such a provider.
Entities that existed in the same ownership structure before enactment must divest within 2 years; acquisitions after enactment must be divested within 1 year, though those clocks pause during any Clayton Act Section 7A waiting-period review.
HHS OIG, DOJ Antitrust, the FTC, and state attorneys general can sue for injunctive relief, forced divestiture, and disgorgement; disgorged funds are to be deposited in an FTC-created fund for harmed communities.
Any required divestiture must be reported to the FTC and DOJ under Clayton Act Section 7A without regard to normal size thresholds, and the agencies must review effects on competition and financial viability.
The bill amends Medicare Advantage law to prohibit contracting with noncompliant MA organizations beginning plan year 2026, requires MA compliance certifications, and treats claims by violators as false claims under federal law.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the ‘‘Patients Over Profit Act’’ or ‘‘POP Act.’
Prohibition on common ownership
Creates the core statutory prohibition: no person may directly or indirectly own, operate, or control any part of both an applicable provider (or an MSO with a management services agreement to such a provider) and a health insurance issuer. The statutory ‘‘person’’ maps to the Sherman Act definition, so corporations, individuals, partnerships, and similarly situated entities fall within the ban. Practically, this reaches indirect control vehicles and layered ownership structures, not only obvious parent-subsidiary arrangements.
Mandatory divestiture windows
Sets fixed timelines for correcting violations: 2 years to divest pre‑existing combinations and 1 year to divest acquisitions made after enactment. The provision forces acquirers and owners to choose which asset to sell (insurance or provider/MSO) and creates a statutory clock that will drive urgent M&A activity, carve-outs, or fire-sales if the law takes effect.
Civil enforcement and remedies
Authorizes civil suits by HHS OIG, the DOJ Antitrust Division, the FTC, or state attorneys general to obtain cease-and-desist orders, divestiture, and disgorgement of revenue earned during the violation. The court-ordered disgorgement must be transferred into an FTC-created fund for use in serving the harmed community; this provision also preserves private rights of action and does not foreclose other remedies under law.
FTC and DOJ review, Clayton Act reporting
Requires that any statutory divestiture be reported to the FTC and the DOJ under Clayton Act Section 7A irrespective of the usual reporting thresholds, and tolls the divestiture clock while any Section 7A waiting period is pending. The FTC and DOJ must evaluate both immediate divestiture effects and the competition/financial viability impacts of subsequent acquisitions by buyers, effectively adding agency oversight over who may acquire divested assets.
Rulemaking and preservation of other authorities
Directs the FTC to issue implementing rules and clarifies that the statute does not narrow other enforcement powers of the FTC, DOJ, HHS, or state attorneys general. In practice, the rulemaking will be the vehicle for defining practical compliance elements (e.g., attribution of control, reporting formats), but the statute requires rules ‘‘not to diminish’’ the section’s obligations.
Medicare Advantage/Part D enforcement and definitions
Amends the Social Security Act to bar contracting and payment to MA organizations that have the prohibited ownership relationships beginning in plan years on or after January 1, 2026, requires MA organizations to submit compliance certifications, and deems claims submitted by violators to be false claims under federal law. The bill also clarifies key terms—applicable provider (with exclusions for hospitals, CAHs, rural emergency hospitals, pharmacies, and DME suppliers), management services agreement, MSO, and health insurance issuer—so stakeholders can identify covered relationships.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries concerned about insurer-driven steering — the measure aims to reduce incentives for an insurer-owned provider to prioritize profits over care choices, which could protect patient choice and limit self‑referral incentives.
- Independent physician groups and clinician-owned practices that compete with insurer‑owned provider chains — removing integrated insurer owners may preserve market access and bargaining leverage for standalone providers.
- Competing payers and new market entrants — the ban may lower barriers to entry for insurers that do not own provider assets by limiting the advantages of vertically integrated counterparts.
Who Bears the Cost
- Health insurance issuers, MA organizations, and owner groups that currently hold both insurance and MSO/provider assets — they must restructure, sell assets, or exit lines of business, potentially at depressed prices or with transaction costs.
- Private equity firms and strategic acquirers holding mixed portfolios — forced divestitures could crystallize losses, change investment valuations, and disrupt portfolio strategies that rely on payer-provider synergies.
- Medicare Advantage enrollees and networks — rapid divestitures or buyer changes can disrupt provider networks, care continuity, and negotiated rates, at least in the short term, while MA organizations reorganize to comply.
- Federal and state enforcement agencies — the statute expands jurisdictions and creates additional review and litigation workload (Clayton Act reporting without thresholds, divestiture reviews, and court actions).
Key Issues
The Core Tension
The central dilemma is between curbing insurer‑driven conflicts of interest through a structural ban on common ownership versus preserving integrated payer-provider models that can coordinate care and realize efficiency gains; the statute prevents certain profit‑seeking arrangements but risks disrupting legitimate care models and patient access where integration has functional benefits.
The bill forces a blunt structural remedy on complex vertical relationships. That raises immediate implementation puzzles: how to attribute ‘‘control’’ through multi‑tier holding companies, common investors, or contractual rights; whether management services agreements with varying degrees of operational control will be treated the same; and how the FTC will calibrate rules that determine when an MSO’s connections count as ownership of a provider.
Those definitional and attribution questions will drive litigation and rulemaking, and they will determine whether the statute captures intended targets or creates loopholes for contractual workarounds.
Divestiture logistics pose a second set of risks. Forcing sales within one- or two‑year windows can leave sellers with few viable buyers, threatening the financial viability of the divested provider or harming patient access if a buyer cannot sustain operations.
The statutory requirement that divestitures be reported without regard to Clayton Act thresholds and the FTC/DOJ mandate to assess buyers’ effects on competition could slow sales and concentrate divested assets in a small set of approved buyers, creating unintended consolidation. Finally, the statute exempts hospitals, pharmacies, and DME suppliers from the ‘‘applicable provider’’ definition, which may incentivize parties to shift assets or services into excluded categories to preserve integrated arrangements—an outcome the bill’s architects likely did not intend.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.